Bill Summaries: H 287 EDUCATE PATIENTS ABOUT OPIOID ANTAGONISTS.

Printer-friendly: Click to view
Tracking:
  • Summary date: Apr 4 2023 - View Summary

    House committee substitute to the 2nd edition makes the following changes. Expands the exemption to new GS 90-12.8 (setting forth a requirement to provide opioid antagonist education) to include a veterinarian acting in the practice of veterinary medicine, at an animal health center, emergency facility, mobile facility, veterinary clinic, or veterinary hospital.


  • Summary date: Mar 21 2023 - View Summary

    House committee substitute to the 1st edition makes the following changes.  Exempts practitioners providing hospice services to a hospice patient from GS 90-12.8 (setting forth requirements pertaining to opioid antagonist education). 


  • Summary date: Mar 7 2023 - View Summary

    Enacts new GS 90-12.8 requiring a practitioner to do the following when prescribing a specified Schedule II controlled substance (opium, opiate, or opioid and any salt, compound, derivative, or preparation of opium and opiate, opium poppy and poppy straw, and cocaine and related items): (1) provide information regarding all of the following to each patient receiving the prescription: the potential dangers of opioids, overdose prevention, and the availability and use of a drug approved by the federal Food and Drug Administration as an opioid antagonist for the complete or partial reversal of opioid-induced respiratory depression; (2) provide this information to one or more persons designated by the patient receiving the prescription or, for minors, to the minor's parent, guardian, or person standing in loco parentis. Defines practitioner as: (1) a physician, dentist, optometrist, veterinarian, scientific investigator, or other person licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or to administer a controlled substance so long as such activity is within the normal course of professional practice or research in this State or (2) a pharmacy, hospital, or other institution licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or to administer a controlled substance so long as such activity is within the normal course of professional practice or research in this State.

    Requires pharmacists to do the following when dispensing those same Schedule II controlled substances: (1) make available the information described above that is consistent with the federal Food and Drug Administration's labeling requirements for opioid pain medication and medication to treat opioid use disorder announced in the specified document and (2) post signage in a conspicuous place containing the same information.

    Specifies that nothing in this statute limits a practitioner's liability for negligent diagnosis or treatment of a patient, as allowed under applicable State or federal law, or constitute negligence per se or creates a private right of action against any practitioner who fails to follow the requirements of this statute.

    Effective October 1, 2023.